"Receptors, KIR3DL2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A KIR receptor that has specificity for HLA-A3 ANTIGEN. It is an inhibitory receptor that contains D0, D1, and D2 extracellular immunoglobulin-like domains and a long cytoplasmic tail.
| Descriptor ID |
D054347
|
| MeSH Number(s) |
D12.776.543.750.705.895.500.750
|
| Concept/Terms |
Receptors, KIR3DL2- Receptors, KIR3DL2
- KIR3DL2 Receptors
- Killer Cell Immunoglobulin-Like Receptor 3DL2
- Killer Cell Immunoglobulin Like Receptor 3DL2
- CD158k Antigen
- Antigen, CD158k
- CD158k Antigens
- Antigens, CD158k
- p140-KIR3DL2 Inhibitory Receptor
- Inhibitory Receptor, p140-KIR3DL2
- Receptor, p140-KIR3DL2 Inhibitory
- p140 KIR3DL2 Inhibitory Receptor
- KIR3DL2 Receptor
- Receptor, KIR3DL2
|
Below are MeSH descriptors whose meaning is more general than "Receptors, KIR3DL2".
Below are MeSH descriptors whose meaning is more specific than "Receptors, KIR3DL2".
This graph shows the total number of publications written about "Receptors, KIR3DL2" by people in this website by year, and whether "Receptors, KIR3DL2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, KIR3DL2" by people in Profiles.
-
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 08; 20(8):1160-1170.
-
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug; 27(8):691-697.
-
KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia. Br J Dermatol. 2018 07; 179(1):197-199.
-
KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 12 28; 130(26):2900-2902.
-
Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity. Blood. 2017 09 21; 130(12):1468-1471.
-
Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome. Clin Cancer Res. 2017 Jul 15; 23(14):3619-3627.
-
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014 Nov 01; 74(21):6060-70.